Furthermore, a query of BRCA1- or BRCA2-mutant ovarian cancer patients from The Cancer Genome Atlas revealed that high PTIP expression correlated with better progression-free survival (PFS) compared to low PTIP expression, which correlated with low PFS. This evidence concerns the gene PAXIP1 and ovarian carcinoma.